Felix Baker
Directeur/Membre du Conseil chez KYMERA THERAPEUTICS, INC.
Fortune : 22 M $ au 31/05/2024
Profil
Felix James Baker is the founder and the Managing Member of Baker Bros.
Advisors LP, which was founded in 2000.
He is currently the Lead Independent Director at Kiniksa Pharmaceuticals Ltd., Independent Director at IGM Biosciences, Inc., Director at Kiniksa Pharmaceuticals Corp., Independent Director at Kodiak Sciences, Inc., Lead Independent Director at Kymera Therapeutics, Inc., Independent Director at Bicycle Therapeutics Plc, Manager at Fbb2 LLC, Co-Managing Partner at Baker Bros.
Advisors GP LLC, Partner at FBB Associates, and Trustee at Memorial Sloan Kettering Cancer Center.
Dr. Baker's former positions include Chairman at Seagen Inc., Chairman at Synageva BioPharma Corp., Chairman at Talis Biomedical Corp., Director at Neurogen Corp., Independent Director at Alexion Pharmaceuticals, Inc., Director at Trimeris, Inc., Director at AnorMED, Inc., Director at ConjuChem, Inc., Independent Director at Genomic Health, Inc., Director at ConjuChem Biotechnologies, Inc., Director at SlipChip Corp., Independent Director at Ardea Biosciences, Inc., Director at Aquinox Pharmaceuticals, Inc., Director at Presidio Pharmaceuticals, Inc., Director at ConjuChem Biotechnologies, Inc., and Owner at VaxGen, Inc.Dr. Baker received his undergraduate and doctorate degrees from Stanford University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INCYTE CORPORATION
0,13% | 15/04/2024 | 281 190 ( 0,13% ) | 16 M $ | 31/05/2024 |
BEIGENE LTD
0,03% | 14/11/2023 | 311 143 ( 0,03% ) | 4 M $ | 31/05/2024 |
| 29/05/2024 | 102 876 ( 0,06% ) | 2 M $ | 31/05/2024 | |
| 15/04/2024 | 37 000 ( 0,09% ) | 703 370 $ | 31/05/2024 | |
CERUS CORPORATION
0,01% | 31/12/2023 | 19 864 ( 0,01% ) | 35 557 $ | 31/05/2024 |
IGM BIOSCIENCES, INC.
0,01% | 28/03/2024 | 2 216 ( 0,01% ) | 18 459 $ | 31/05/2024 |
TSCAN THERAPEUTICS, INC.
-.--% | 19/04/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Felix Baker
| Sociétés | Poste | Début |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Directeur/Membre du Conseil | 01/10/2015 |
| KODIAK SCIENCES INC. | Directeur/Membre du Conseil | 01/09/2015 |
| IGM BIOSCIENCES, INC. | Directeur/Membre du Conseil | 26/01/2021 |
| KYMERA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 28/03/2024 |
| BICYCLE THERAPEUTICS PLC | Directeur/Membre du Conseil | 18/04/2024 |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Fondateur | 01/01/2000 |
Kiniksa Pharmaceuticals Corp.
 Kiniksa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The company is based in Lexington, MA. The CEO of the company is Sanj K. Patel. | Directeur/Membre du Conseil | - |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
| FBB Associates | Corporate Officer/Principal | - |
| ░░░░░ ░░░░░ ░░░░░░░░ ░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Anciens postes connus de Felix Baker
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Felix Baker
| Stanford University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| BICYCLE THERAPEUTICS PLC | Health Technology |
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| IGM BIOSCIENCES, INC. | Health Technology |
| KYMERA THERAPEUTICS, INC. | Health Technology |
| KODIAK SCIENCES INC. | Health Technology |
| TALIS BIOMEDICAL CORPORATION | Health Technology |
| Entreprise privées | 21 |
|---|---|
Neurogen Corp.
 Neurogen Corp. Pharmaceuticals: MajorHealth Technology Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
VaxGen, Inc.
 VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
AnorMED, Inc.
 AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | Health Technology |
ConjuChem, Inc.
 ConjuChem, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem, Inc. is a biotechnology company that has developed the Drug Affinity Complex (DAC™) Technology, a platform enabling the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. | Health Technology |
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Finance |
Genomic Health, Inc.
 Genomic Health, Inc. Medical SpecialtiesHealth Technology Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA. | Health Technology |
ConjuChem Biotechnologies, Inc. /Old/
 ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Health Technology |
| Fbb2 LLC | |
| Baker Bros. Advisors GP LLC | |
| SlipChip Corp. | |
| FBB Associates | |
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Health Services |
Ardea Biosciences, Inc.
 Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Presidio Pharmaceuticals, Inc.
 Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Health Technology |
ConjuChem Biotechnologies, Inc.
 ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Kiniksa Pharmaceuticals Corp.
Kiniksa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The company is based in Lexington, MA. The CEO of the company is Sanj K. Patel. | Health Technology |
